Paul Wotton Buys 69,767 Shares of Cynata Therapeutics Limited (ASX:CYP) Stock

Cynata Therapeutics Limited (ASX:CYP) insider Paul Wotton bought 69,767 shares of the business’s stock in a transaction dated Thursday, February 20th. The shares were purchased at an average cost of A$0.30 ($0.19) per share, with a total value of A$20,930.10 ($13,331.27).

Cynata Therapeutics Stock Performance

The stock has a market cap of $57.60 million, a P/E ratio of -4.70 and a beta of 0.93.

About Cynata Therapeutics

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease.